BeOne Medicines Ltd. (ONC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
BeOne Medicines Ltd. (ONC) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (88% profit margin, 11% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How ONC Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $5.34B | 87.5% | 8.4% | $286.9M | $941.7M | 45.5% |
| FY 2024 | $3.81B | 84.4% | -14.9% | -$644.8M | -$633.3M | -45% |
| FY 2023 | $2.46B | 44% | -49.1% | -$881.7M | -$1.27B | -6.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ONC)
- ✓Live walkthrough of ONC's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ONC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +40.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ONC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ONC. Explore sector supply chains on /butterfly.
ONC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is BeOne Medicines Ltd. (ONC)?
In FY 2025 (10-K), ONC converted $5.3B of revenue into a 87.5% gross margin, 8.4% operating margin, and $941.7M in free cash flow (17.6% FCF margin).